Skip to main content

Table 1 GD management – the future

From: How to use thionamide anti-thyroid drug in the young– what’s new?

• The relationship between ATD duration beyond 5 years and likelihood of relapse needs to be established in greater detail.
• The baseline immune and genetic factors that may impact on the likelihood of remission need to be explored in more detail. This may help to predict outcome.
• Patients can potentially be stratified as at low or high risk of an adverse reaction to ATD including agranulocytosis with associated alterations in surveillance program.
• The potential role of long-term iodine therapy needs to be explored in more detail.
• The role of existing and novel immunomodulatory agents needs to be explored.